Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Southern California
With
Aventis Pharmaceuticals
Eli Lilly and Company
Primary Objective:
1\. To determine the response rate, time to progression and survival (secondary) of the combination of docetaxel and gemcitabine administered on a weekly basis to patients with platinum-resistant ovarian cancer
Secondary Objective:
1. To determine the toxicity of this combination regimen in patients with platinum-resistant ovarian cancer
2. To evaluate the toxicity and safety profile of a short course (one dose) of premedication with steroids to patients receiving weekly gemcitabine and docetaxel
OUTLINE: Patients receive gemcitabine IV over 30 minutes on days 1 and 8, and docetaxel IV over 60 minutes on day 8. Treatment repeats every 21 days until PD, unacceptable toxicity, or patient's withdrawal.
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Histologically proven diagnosis of epithelial ovarian ca
Must have platinum-resistant disease. (Defined as progression during the most recent platinum-based chemotx or relapse \< 6 months after the most recent platinum-based chemotx regimen.)
You may not be if
Greater than or equal to 18 years of age
GOG performance status less than or equal to 2
AGC/ANC greater than or equal to 1.5; platelets greater than or equal to 100,000; hemoglobin (Hgb) greater than or equal to 8.0.
Creatinine less than or equal to 2.0
Total bilirubin less than or equal to upper limit of normal (uln)
Fully recovered from acute toxicities secondary to prior treatment (tx)
Signed informed consent
Prior treatment with gemcitabine or docetaxel
Underlying medical, psychiatric, or social conditions that would preclude patient from receiving treatment
Peripheral neuropathy greater than or equal to Grade 2